Sign in

You're signed outSign in or to get full access.

David Amsalem

Managing Director and Senior Research Analyst at Piper Sandler

David Amsellem is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in coverage of the healthcare sector with a particular emphasis on biotechnology and specialty pharmaceuticals. He covers over 60 companies including Alkermes, SAGE Therapeutics, and Indivior, and is known for his in-depth analysis and frequent participation in major healthcare earnings calls. On TipRanks, Amsellem holds a 1.56-star rating based on a track record with a 45% success rate covering 64 stocks, reflecting challenging market conditions in the sector. With over a decade at Piper Sandler and prior roles at other leading financial firms, he holds multiple securities licenses and is registered with FINRA, recognized for his expertise in evaluating complex healthcare investment opportunities.

David Amsalem's questions to Alkermes (ALKS) leadership

Question · Q3 2025

David Amsalem asked about the potential for additional orexin candidates (AUX4510, AUX7290) to target psychiatric settings and the company's strategy for Elixerextant outside the U.S., including discussions with European regulators and pricing.

Answer

Richard Pops, CEO, confirmed interest in psychiatry, neurology, and rare neurodevelopmental/neurodegenerative settings for the next candidates, aiming for patient-focused studies by the end of 2026. For Elixerextant ex-U.S., he noted ongoing clinical trials in Europe and Asia, expecting pricing to be similar to the U.S. market.

Ask follow-up questions

Fintool

Fintool can predict Alkermes logo ALKS's earnings beat/miss a week before the call